Literature DB >> 23243005

Successful treatment of pulmonary hypertension with beraprost and sildenafil after cord blood transplantation for infantile leukemia.

Nozomu Kawashima1, Masanobu Ikoma, Yuko Sekiya, Atsushi Narita, Nao Yoshida, Kimikazu Matsumoto, Tameo Hatano, Koji Kato.   

Abstract

Pulmonary hypertension (PH) is an infrequently reported complication after hematopoietic stem cell transplantation, and its etiology and therapeutic strategies, especially in infants, remain unclear. We report a case of severe PH that developed in an infant with acute leukemia following administration of busulfan as a preconditioner for cord blood transplantation; the case was successfully treated with sildenafil and beraprost, which to our knowledge is the first reported successful use of this regimen in PH following transplantation for infantile leukemia. From a review of all previous reports, use of busulfan in infants may raise the risk of developing PH, and unlike definitive pulmonary veno-occlusive disease, PH in this subgroup may be reversible by early detection and treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23243005     DOI: 10.1007/s12185-012-1246-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  13 in total

Review 1.  Pulmonary veno-occlusive disease: recent progress and current challenges.

Authors:  David Montani; Dermot S O'Callaghan; Laurent Savale; Xavier Jaïs; Azzedine Yaïci; Sophie Maitre; Peter Dorfmuller; Olivier Sitbon; Gérald Simonneau; Marc Humbert
Journal:  Respir Med       Date:  2010-04-24       Impact factor: 3.415

2.  Pulmonary hypertension in two severe combined immunodeficiency disease patients posthaematopoietic stem cell transplantation.

Authors:  Robbert G M Bredius; Maria Ouachee; Ronald van Brempt; Regina Bökenkamp; Arjan C Lankester; Koert M Dolman; R Maarten Egeler; Alain Fischer
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

3.  Pulmonary veno-occlusive disease following reduced-intensity allogeneic bone marrow transplantation for acute myeloid leukemia.

Authors:  Kohei Hosokawa; Hirohito Yamazaki; Masaru Nishitsuji; Satoshi Kobayashi; Akiyoshi Takami; Masaki Fujimura; Shinji Nakao
Journal:  Intern Med       Date:  2012-01-15       Impact factor: 1.271

Review 4.  Reversible course of pulmonary arterial hypertension related to bone marrow transplantation.

Authors:  Alisa Limsuwan; Samart Pakakasama; Suradej Hongeng
Journal:  Heart Vessels       Date:  2011-01-07       Impact factor: 2.037

5.  Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Russel Hirsch; Benjamin Laskin; Stella Davies; David Witte; Ranjit Chima
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-06       Impact factor: 5.742

6.  Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis.

Authors:  C G Steward; I Pellier; A Mahajan; M T Ashworth; A G Stuart; A Fasth; D Lang; A Fischer; W Friedrich; A S Schulz
Journal:  Br J Haematol       Date:  2004-01       Impact factor: 6.998

7.  Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease.

Authors:  Arnaud Resten; Sophie Maitre; Marc Humbert; Anne Rabiller; Olivier Sitbon; Frédérique Capron; Gérald Simonneau; Dominique Musset
Journal:  AJR Am J Roentgenol       Date:  2004-07       Impact factor: 3.959

Review 8.  Pathophysiological basis for anticoagulant and antithrombotic therapy in pulmonary hypertension.

Authors:  Antonio Augusto Lopes
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2006-01

9.  A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats.

Authors:  Takefumi Itoh; Noritoshi Nagaya; Takafumi Fujii; Takashi Iwase; Norifumi Nakanishi; Kaoru Hamada; Kenji Kangawa; Hiroshi Kimura
Journal:  Am J Respir Crit Care Med       Date:  2003-10-02       Impact factor: 21.405

10.  Pulmonary hypertension complicating bone marrow transplantation for idiopathic myelofibrosis.

Authors:  Sadhna Shankar; John K Choi; Terence S Dermody; David R Head; Nancy Bunin; Robert Iannone
Journal:  J Pediatr Hematol Oncol       Date:  2004-06       Impact factor: 1.289

View more
  3 in total

1.  Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.

Authors:  A V Desai; M B Heneghan; Y Li; N J Bunin; S A Grupp; R Bagatell; A E Seif
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

2.  Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.

Authors:  Ami V Desai; Alix E Seif; Yimei Li; Kelly Getz; Brian T Fisher; Vera Huang; Adjoa Mante; Richard Aplenc; Rochelle Bagatell
Journal:  Pediatr Blood Cancer       Date:  2016-01-21       Impact factor: 3.167

Review 3.  Pediatric pulmonary arterial hypertension.

Authors:  Dan-Chen Wu; Hong-Da Zhang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.